You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic FilariasisSBC: NANOCOMPOSIX, INC. Topic: NIAID
Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of nanoscale confocal photothermal IR micro spectroscopy n CPIRSBC: Anasys Instruments Corp. Topic: 100
Abstract This proposal will lead to a Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of sub micron confocal photothermal IR micro spectroscopy CPIR Label free sub micron chemical imaging and spectroscopy has long been sought for visualization of biomolecules and materials in complex living systems Many diseases first manifest ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode ArraySBC: CYION TECHNOLOGIES LLC Topic: NIBIB
Summary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: CoPlex Therapeutics, LLC Topic: NIA
ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: Epigen Biosciences, Inc. Topic: 101
SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: WinSanTor, Inc. Topic: 101
PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: NALAS ENGINEERING SERVICES INC Topic: DTRA14B001
Nalas Engineering and Johns Hopkins University collaborated in a Phase I STTR program to study reactive mixtures of HI3O8 and nanocomposite fuels previously developed by the Weihs Group. These fuel/oxidizer mixtures are uniquely able to simultaneously produce heat and biocidal iodine gas, a combination designed to destroy biological weapons. The team at Nalas focused on evaluating conditions for p ...STTR Phase II 2017 Department of DefenseDefense Threat Reduction Agency
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagentsSBC: BIOVENTURES, INC Topic: 172
Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
A Systematic Medical Approach to Reward Transformation SMART for Brain Health in Opioid Use DisorderSBC: Versa Integrated Solutions, Inc. Topic: 102
Summary In recent years opioid use disorder OUD and deaths due to opiate overdose e g with heroin fentanyl oxycodone in suburban and rural non minority groups has created an urgency for approaches to stem this epidemic but the rise in OUD and opiate overdose deaths has occurred in inner cities at similar rates Heroin misuse and addiction are persistent problems in African American commu ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
Polyionic Papillomavirus like Particles VLP for the Treatment of HPV oropharyngeal squamous cell carcinomas OPCsSBC: PATHOVAX LLC Topic: 102
The broader impact commercial potential of PathoVax s STTR phase I proposal is to improve outcomes of cancer immuno therapy utilizing a vaccine formulation combining an immunogenic chimeric virus like particle cVLP vaccine with FDA approved immune check point inhibitors PathoVax proposes to develop this technology for treatment of human papillomavirus HPV associated cancers However cancer ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health